FDA ALERT
FDA ALERT
11/15/2023
Jessica Ganga
In late September, the FDA approved the first biosimilar to tocilizumab to treat adult and pediatric patients with various indications of arthritis.
11/15/2023
research summary
research summary
06/21/2023
Leigh Precopio
Researchers examined the efficacy and safety of a humanized monoclonal antibody for the treatment of active psoriatic arthritis in some patient populations.
06/21/2023
Research Summary
Research Summary
02/27/2023
Researchers examined the association between inflammation-reducing medications and dementia risk in patients with rheumatoid arthritis.
02/27/2023
Health Outcomes
Health Outcomes
02/17/2021
A new app allows patients with rheumatic and musculoskeletal diseases to choose which measures of disease activity to track—and the results can help direct personalized treatment.
02/17/2021
Diagnosis
Diagnosis
07/01/2020
The ACR and EULAR updated their criteria for classifying systemic lupus erythematosus in 2019. How did the newer criteria perform compared with earlier systems of classification? Read more to find out. ...
07/01/2020
Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
06/18/2020
Researchers compared rates of in-hospital mortality among patients with and without systemic lupus erythematosus to determine the trends and risk factors associated with death related to SLE.
06/18/2020
Treatment
Treatment
06/17/2020
The drug was given priority review status by the FDA and was approved to treat adults with the rare, severe autoimmune disease.
06/17/2020
cardiovascular disease
cardiovascular disease
06/08/2020
Researchers conducted a literature review to find out whether existing predictive tools accurately predict whether patients with rheumatic diseases will develop cardiovascular diseases.
06/08/2020
Treatment
Treatment
04/02/2020
Because immunometabolism is involved in the pathogenesis of SLE, the researchers aimed to determine whether repurposing metformin could control the immunometabolic processes in patients with systemic lupus...
04/02/2020
Gout
Gout
02/07/2020
In a new population-based study, the authors sought to assess the risk of hypersensitivity reactions with allopurinol and febuxostat use among persons aged 65 years or older.
02/07/2020